Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
Environmental Pollution (Barking, Essex : 1987)|September 8, 2023
Physicochemical and biological changes on naturally aged microplastic surfaces in real environments over 10 monthsXue Yu, Bing Wang, Chenglong Han, et al.
The Journal of Rheumatology|October 17, 2007
Association of anemia and physical disability among patients with rheumatoid arthritisChenglong Han, Mahboob U Rahman, Mittie K Doyle, et al.
The Journal of Rheumatology|April 17, 2012
Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD studyMark C Genovese, Chenglong Han, Edward C Keystone, et al.
Journal of Patient-Reported Outcomes|November 14, 2023
Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel diseaseBrian G Feagan, William J Sandborn, Bruce E Sands, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 9, 2020
Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT TrialM Elaine Husni, Arthur Kavanaugh, Eric K H Chan, et al.
The Journal of Rheumatology|December 17, 2015
Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD TrialEdward C Keystone, Mark C Genovese, Stephen Hall, et al.
Gene|December 13, 2021
Low expression of bestrophin-2 is associated with poor prognosis in colon cancerLi Wang, Huawei Zhu, Weiliang Sun, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 9, 2020
Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE TrialJohn D Reveille, Atul Deodhar, Akgun Ince, et al.
Arthritis Research & Therapy|July 15, 2021
Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritisProton Rahman, Philip J Mease, Philip S Helliwell, et al.
The Lancet. Gastroenterology & Hepatology|January 16, 2026
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trialMillie Long, Jessica R Allegretti, Silvio Danese, et al.
Pageof 9